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C/EBP = CCAAT/enhancer binding protein; CHOP = C/EBP homologous protein-10; CUGBP1 = CUG triplet repeat binding protein; IL = inter-
leukin; LAP = liver-enriched activating protein; LIP = liver-enriched inhibitory protein; NF = nuclear factor; PCR = polymerase chain reaction; RT =
reverse transcriptase; uORF = upstream open reading frame.
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Introduction
Breast cancer is, in part, a result of the overexpression of
transcription factors that disrupt the delicate balance
between cellular proliferation, terminal differentiation and
programmed cell death. Yet, when expressed at physio-
logic levels, many of these same transcription factors are
critical for normal development of the mammary gland. The
C/EBPs play a pivotal role in controlling growth and differ-
entiation of the mammary gland. Accordingly, this review
focuses on the role that the C/EBPs play in both breast
cancer and in normal mammary development.
The C/EBPs together form a highly conserved family of tran-
scription factors that bind to sequence-specific DNA
sequences as dimers and that regulate the transcription of
genes involved in proliferation and differentiation. Six C/EBP
genes have thus far been identified, and they are designated
C/EBPα, C/EBPβ, C/EBPγ, C/EBPδ, C/EBPε, and
C/EBPζ (also known as CHOP [C/EBP homologous
protein-10] or GADD153) (for a review of the nomenclature,
see [1]). Of these genes, C/EBPβ, C/EBPα, and C/EBPδ
have been the most thoroughly studied in rodent and human
mammary tissue, and will be the focus of this review.
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C/EBPs belong to the leucine zipper class of DNA-
binding proteins. They contain an amino-terminal transacti-
vation domain and a highly basic DNA-binding region
immediately adjacent to the carboxyl-terminal, leucine-rich
dimerization domain (Fig. 1).
The dimerization domain is characterized as an amphi-
pathic, α-helix containing a heptad repeat of leucines that
project uniformly along the hydrophobic side of the helix
and that interdigitate with the leucine residues of a dimer-
ization partner [2]. Dimerization can occur within a C/EBP
family, between different C/EBP family members, or
between different groups of leucine zipper proteins [3].
Dimerization of these helices has been proposed to bring
into close proximity the basic amino acids associated with
the DNA binding domain from the two polypeptide chains
[2,4]. Dimerization is consequently a prerequisite to DNA
binding and, when not bound to DNA, the dimers readily
dissociate back to monomers [3].
With the exception of C/EBPε and  CHOP, all of the
C/EBP genes are intronless and transcription results in a
single mRNA that is translated to yield multiple protein iso-
forms. During mammary gland development, C/EBPβ,
C/EBPα and  C/EBPδ are differentially and temporally
expressed to coordinately control mammary growth, differ-
entiation, and programmed cell death.
Expression of C/EBPs during mammary
gland development
C/EBPβ β gene
C/EBPβ is expressed in numerous tissues, including the
liver, adipose tissue, the intestine, the ovary, the lung, the
mammary gland, skin, the brain, the kidney, the heart and
hematopoietic tissues. Transcription of the intronless
C/EBPβ gene results in a single 1.4 kb mRNA that can be
translated via alternative start sites into three isoforms: full-
length, 38 kDa liver-enriched activating protein (LAP)1;
35 kDa LAP2; and 20 kDa liver-enriched inhibitory protein
(LIP).
The most abundant and easily detected isoforms in the
mouse mammary gland are LAP2 (35 kDa) and LIP
(20 kDa). In human breast tissue, the LAP isoforms are
larger (approximately 42–46 kDa) and the LIP isoform
remains unchanged at 20 kDa. This increase in size of the
LAP isoforms is due to an additional 49 amino acid
residues located in the N-terminal portion of the human
C/EBPβ protein that are excluded from the LIP isoform. A
larger LAP isoform (55 kDa) has also been reported in
nontransformed, human mammary cells [5].
Both the LAP and LIP isoforms have the same DNA
binding and dimerization domains but, due to translation
at an alternative downstream start codon, LIP lacks
Figure 1
CCAAT/enhancer binding protein beta (C/EBPβ) mRNA is translated into multiple protein isoforms. Schematic representation of C/EBPβ mRNA,
its three potential translation start sites and the resultant protein isoforms. The transactivation domain, the DNA binding domain (DNA) and the
leucine zipper, dimerization domain (Zipper) are indicated. It has been suggested that the upstream open reading frame (uORF) is located within a
stem loop structure, and the LAP translation start sites are shown positioned on either side of the uORF. Alternative isoforms, in addition to those
represented in this figure, may be present in other tissues and species. LAP, liver-enriched activating protein; LIP, liver-enriched inhibitory protein;
UTR, untranslated region.115
much of the trans-activation domain (Fig. 1). LIP is con-
sequently unable to activate gene transcription [6]. As
with all C/EBP family members, LAP and LIP are capable
of forming homodimers or heterodimers with each other.
Also, LIP can antagonize the transcriptional activating
potential of LAP by competing for DNA binding sites as
a homodimer or by its interaction in a LAP/LIP het-
erodimer [6]. Because of an increased DNA affinity of
the LIP isoform, this inhibition of transcriptional activity
can occur even at substoichiometric ratios of LIP/LAP,
thereby suggesting a dominant-negative function for LIP
[6]. LAP and LIP thus have opposing actions on gene
activation, and the LAP/LIP ratio, rather than their
absolute amounts, may be an important indicator of
C/EBPβ transcriptional activity.
C/EBPβ β mRNA
C/EBPβ mRNA expression levels are detectable in the
virgin gland. These expression levels increase during preg-
nancy, decline during lactation, and increase again during
the onset of involution [7].
C/EBPβ β protein
C/EBPβ-LAP2 is detected in whole cell extracts of the
virgin rat gland and is elevated twofold to threefold with
the onset of pregnancy. Although LAP levels decrease at
parturition, they are readily detectable throughout lacta-
tion and involution [8]. The LIP isoform is expressed at
very low levels in the virgin gland and is dramatically
upregulated (100-fold) during pregnancy [8]. LIP then
decreases to nearly undetectable levels at parturition and
remains low throughout lactation [8]. Similar protein
expression profiles have been observed in the mouse
mammary gland [9].
In summary, the C/EBP-LAP isoform, although variable in
expression levels, is detectable at all stages of mammary
gland development. The LIP isoform, however, is most
readily detected during pregnancy, a period of rapid epithe-
lial cell proliferation. The expression profile of the C/EBPβ
isoforms is in part regulated by lactogenic hormones (e.g.
glucocorticoids), and it reflects the importance of the iso-
forms in the expression of milk protein genes such as β-
casein and whey acidic protein [8,10,11].
C/EBPα α gene
C/EBPα is not as widely expressed as C/EBPβ, and is
detected in the liver, adipose tissue, the mammary gland,
the lung, the intestine, the adrenal gland, the placenta, and
peripheral blood mononuclear cells. The intronless
C/EBPα gene encodes a 2.7 kb mRNA that is translated
into 42 and 30 kDa isoforms via a leaky ribosome scan-
ning mechanism [6]. As was observed for C/EBPβ-LIP,
the truncated 30 kDa isoform of C/EBPα is not as potent
a transactivator of gene expression as the full-length
42 kDa isoform [12,13].
C/EBPα α mRNA
Reports on the expression profile for C/EBPα in the
mammary gland are not in complete agreement. Some
data suggest that C/EBPα levels are the most easily
detected in the virgin gland, but are generally low and
remain unchanged throughout mouse mammary gland
development [9,14]. It has also been hypothesized that
the low level of expression observed for C/EBPα mRNA
during lactation is the result of a dilutional effect from
overly abundant milk protein RNAs [9]. Other workers
have demonstrated that C/EBPα mRNA is high during the
early stages of lactation, expressed at lower levels during
the late stages of lactation/early involution, and increases
again during late involution [15]. It is consequently uncer-
tain whether the cascade model of C/EBP regulation,
which has been proposed in adipocyte differentiation and
which results in activation of C/EBPα by  C/EBPβ and
C/EBPδ [16], occurs in the mammary gland.
C/EBPα α protein
Few studies have examined C/EBPα protein expression
during mammary development. Raught et al. demonstrated
that the 42 kDa protein isoform is expressed at high levels
during lactation and at lower levels during involution in the
rat mammary gland [8].
C/EBPδ δ gene
This intronless gene is transcribed as a single mRNA
(1.2 kb) that encodes a 269 amino acid protein and is
expressed in the intestine, adipose tissue, the lung and the
mammary gland. The DNA binding affinity of C/EBPδ is
less than that for C/EBPβ and C/EBPα, but the transacti-
vation potentials are comparable [17]. The expression of
C/EBPδ mRNA during mammary development is different
from that reported for the protein. The reasons for this dis-
crepancy are unclear.
C/EBPδ δ mRNA
C/EBPδ expression is low throughout pregnancy and lac-
tation, but it increases dramatically (>100-fold) within the
first 12 hours of involution. This precedes the induction of
C/EBPβ at 24–48 hours [7].
C/EBPδ δ protein
Developmental expression of C/EBPδ protein in the rat
mammary gland mimics that of C/EBPβ protein. Low
expression levels are present in the virgin/involuted gland,
with the highest levels observed during pregnancy, fol-
lowed by a decrease in expression during early lactation
and an increase in expression towards late lactation [8].
Knockout mice: invaluable tools in the
analysis of mammary gland development
Targeted gene deletions have proven to be an invaluable
tool in the analysis of mammary gland development. Unfor-
tunately, some gene deletions result in a lethal phenotype.
Available online http://breast-cancer-research.com/content/4/3/113116
The mouse mammary gland provides a unique system in
which these lethal phenotypes can be rescued and ana-
lyzed. The mammary fat pad, when cleared of endogenous
epithelial cells, is an ideal site for the transplantation and
analysis of tissue from mice that die embryonically or as
neonates. Additionally, transplantation studies permit the
analysis of epithelial–stromal interactions between tissues
of different genetic backgrounds, as observed in studies
with the C/EBPα and C/EBPβ knockout mice and as dis-
cussed in the following.
C/EBPβ β knockout mice
C/EBPβ-deficient mice were generated by two indepen-
dent groups in 1995 [18,19], and were found to have
defects in mammary gland development. Mammary glands
from C/EBPβ–/– virgin mice exhibited delayed ductal out-
growth, distended ducts and decreased branching [9,14].
The abnormal ductal morphogenesis in the virgin gland
was in part due to a lack of normal ovarian function in the
C/EBPβ–/– mice, and could be partially rescued using
wild-type ovarian transplants and treatment with estradiol
and progesterone. The proliferative rate, the lobuloalveolar
development, and the expression of milk proteins, β-casein
and whey acidic protein, were dramatically inhibited in the
C/EBPβ–/– mouse despite hormone replacement [9,14].
An elegant series of transplantation experiments were
conducted by both these groups to test whether the
impairment in ductal morphogenesis and lobuloalveolar
development was intrinsic to the epithelial cells or was
mediated via stromal and systemic interactions. C/EBPβ–/–,
C/EBPβ–/+, or C/EBPβ+/+ epithelia were transplanted into
wild-type stroma (C/EBPβ+/+) of either host nude mice or
syngeneic mice that had been ‘cleared’ of endogenous
epithelial cells. In the reverse experiment, C/EBPβ+/+ donor
epithelia were transplanted into the cleared stroma of
C/EBPβ–/– mice. Both types of transplantation experiments
demonstrated that the defects in ductal morphogenesis
and in lobuloalveolar development were due to the loss of
C/EBPβ in the epithelia and were not a result of defects in
stromal signaling that may occur due to C/EBPβ deficiency
[9,14]. In conclusion, the C/EBPβ knockout mouse has
proven a useful model in determining that C/EBPβ is criti-
cal for mammary gland development.
C/EBPα α knockout mice
Mice deficient for C/EBPα were also developed in 1995.
Studies of mice homozygous for the targeted deletion are
limited, however, because C/EBPα knockout mice die
within 8 hours of birth due to the defective induction of
liver enzymes essential for glucose metabolism [20]. The
analysis of mammary gland development in C/EBPα–/–
mice was consequently possible only via transplantation
experiments. Seagroves et al. transplanted neonatal
mammary anlagen into the cleared fat pads of syngeneic
hosts and conducted subsequent serial transplantation of
these first generation ductal outgrowths into the cleared
fat pads of additional syngeneic hosts [9]. On whole mount
analysis of the second generation tissue, no differences in
mammary development were detected between the
C/EBPα+/+ or  C/EBPα–/– transplanted glands in virgin,
pregnant, lactating or involuted mice [9]. These experi-
ments demonstrate that although C/EBPα is expressed in
mammary epithelial cells, the deletion of this gene does
not affect normal mammary gland development.
C/EBPβ β C/EBPδ δ double knockout mice
C/EBPδ–/– mice are viable, fertile and, it is assumed, could
lactate and nurse their pups because no mammary gland
abnormalities have been reported [21]. In contrast, 85%
of C/EBPβ–/– C/EBPδ–/– double knockout mice died at the
perinatal or early postnatal stage. No gross abnormalities
were observed in the surviving neonates, but the mice
exhibited defective adipocyte differentiation [21]. No
mammary gland abnormalities have been reported for
these double knockout mice, and it is unknown whether
the gland has been analyzed for defects in development.
C/EBPs in mouse mammary gland tumors
The expression profile of the C/EBPs during mammary
development suggested that C/EBPβ is more involved in
the control of cellular proliferation than the other C/EBP
family members. Previous data in adipocytes [22], in hepa-
tocytes [23], and in regenerating liver [24] have also sup-
ported a role for C/EBPβ in the control of proliferation.
It was hypothesized that the expression of C/EBPβ would
be elevated in situations of uncontrolled proliferation such
as tumorigenesis. C/EBPβ expression was consequently
analyzed in mammary gland tumors from different trans-
genic mouse models as well as in nontumorigenic, hyper-
plastic outgrowths. The C/EBPβ-LAP isoform was
observed in whole cell extracts from both tumors and non-
tumorigenic hyperplastic outgrowths. The LIP isoform,
however, was only detectable in tumor extracts [25].
In summary, C/EBPβ-LIP was overexpressed in rodent
mammary tumors, but not in nontumorigenic hyperplastic
mouse outgrowths. Similar results at the transcriptional
level have been observed in mammary tumors from
MMTV/c-neu transgenic mice. C/EBPβ mRNA expression
was found to be elevated in 100% of mammary tumors
isolated from these ErbB2 overexpressing mice and, inter-
estingly,  C/EBPα mRNA was detected at low levels in
30% of tumors, C/EBPδ mRNA was detected at variable
levels in 50% of the tumors, and CHOP mRNA was
detectable in most of the tumors examined [26].
C/EBPs in human breast cancer specimens
The data from these studies suggested that C/EBPβ plays
a role in tumorigenesis of the rodent mammary gland, but it
was unknown what role this factor may have in human
breast cancer. Our laboratory addressed this question by
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analyzing  C/EBPβ expression levels in infiltrating ductal
carcinoma specimens from 39 women. Both C/EBPβ-LAP
and C/EBPβ-LIP were expressed in approximately 70% of
the tumor extracts examined by western blot analysis.
However, LIP was expressed at high levels (approximately
15 times higher than the levels of LIP in the lower express-
ing or nonexpressing tumors) in 23% of the infiltrating
ductal carcinomas. High levels of LIP were associated with
tumors that were estrogen-negative and progesterone
receptor-negative, were aneuploid, were highly prolifera-
tive, and were poorly differentiated (classified as
Elston–Ellis grade III) [27]. Other researchers have
observed LIP expression in cultured breast cancer cells as
well as in normal human mammary epithelial cells, and have
demonstrated that LAP (55 kDa) is found exclusively in
normal mammary cells but that LAP (46 kDa) is restricted
to dividing cells (both normal and neoplastic) [5].
Breast cancer is commonly surrounded by desmoplasia,
which is an accumulation of fibroblasts that provides
structural and biochemical support for the tumor. It is
believed that the malignant epithelial cells secrete factors
that prevent the differentiation of the stromal fibroblasts to
adipocytes. It has recently been demonstrated that epithe-
lial, breast tumor-derived cytokines can act on the stroma
to cause downregulation of C/EBPα, and act on the per-
oxisome proliferator activated receptor γ to cause the
upregulation of C/EBPβ and C/EBPδ [28]. This increase
in C/EBPβ expression can then mediate aromatase over-
expression in the adipose fibroblasts, which in turn
increases the formation of estrogens and stimulates the
proliferation of the epithelial cells [29].
Although not discussed extensively in the present review,
CHOP has been shown via RT-PCR to be overexpressed in
breast tumor specimens [30]. CHOP can also be induced
in human breast cell lines by glutamine deprivation [31].
These observations are consistent with the hypothesis
that the C/EBPβ isoforms are important for differentiation
and proliferation in the mammary gland. However, these
studies did not directly address the question of whether
overexpression of LIP or LAP is a consequence of prolifer-
ative, uncontrolled growth or whether it actually con-
tributes to tumor development. These types of functionality
studies have been best addressed using transgenic mice
and overexpression in cell culture.
Functionality studies: a role for C/EBPβ β in
breast cancer
C/EBPβ β-LIP transgenic mice
Little is known about how the LAP and LIP isoforms inde-
pendently regulate cell-cycle progression in the intact
mammary gland. Unfortunately, only one transgenic mouse
study has been published to date that investigates the
functional significance of overexpression of the C/EBPβ
isoforms in the mammary gland [32]. Likewise, no trans-
genic mice have been generated that overexpress either
C/EBPα or C/EBPδ in the mammary gland.
C/EBPβ-LIP was overexpressed in the mouse mammary
gland under the control of whey acidic protein sequences
that preferentially target expression to the mouse
mammary gland at day 10 of pregnancy, extending
throughout lactation [32,33]. Mammary gland abnormali-
ties were detected in the involuted glands of multiparous,
aged females. These abnormalities included focal and
diffuse hyperplasia in 30–40% of the glands examined
and, less frequently, mammary intraepithelial neoplasias
(similar to ductal carcinoma in situ) and invasive and non-
invasive carcinomas in 9% of the glands [32]. These
results demonstrated that overexpression of LIP itself was
not sufficient to induce tumorigenesis. Elevated LIP
expression can, however, induce proliferation and hyper-
plasias that may be more susceptible to additional onco-
genic hits.
Cell culture overexpression studies
C/EBPβ gene
The effects of overexpression of either C/EBPβ-LAP or
C/EBPβ-LIP on cell-cycle progression and growth rate
have been analyzed in many different cell lines, but have
recently been examined in immortalized mammary epithe-
lial cells. A study in the HC11 mouse mammary epithelial
cell line demonstrated that growth rate, as observed over
a 72-hour period, was relatively unaffected by the over-
expression of either LIP or LAP [26].
Likewise, our laboratory stably transfected and over-
expressed the C/EBPβ-LIP isoform in the TM3 mouse
mammary epithelial cell line [32]. We also observed that
cells stably expressing LIP did not show abnormalities in
the growth rate during exponential growth, but on reach-
ing confluence (day 7 of culture) some of the cells had
escaped contact inhibition and, by day 15 of culture, at
least 10% of the cells had re-entered the cell cycle and
were forming proliferative foci [32]. The proliferative
effects of LIP overexpression observed in cell culture were
reproduced on transplantation of LIP-expressing TM3 cells
into the cleared fat pad of syngeneic mice [32].
Similar results have been demonstrated during the differen-
tiation of 3T3-L1 adipocytes [34]. LIP was stably introduced
via retroviral gene transfer, and adipogenesis was induced
by standard methods. Cells were examined at day 8 of dif-
ferentiation and it was observed that LIP overexpression
resulted in foci formation and a loss of contact inhibition, as
well as the prevention of terminal adipogenic differentiation
and the induction of a transformed phenotype [34].
Unfortunately, with the exception of the study by Dearth et
al. [26], most studies of LAP overexpression have been
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conducted in nonmammary cells. These experiments have
demonstrated that LAP induces differentiation and/or cell-
cycle arrest in hepatocytes [23], in hematopoietic cells
[35], and in adipocytes [36].
It is clear that additional studies need to be conducted in
mammary epithelial cells to conclusively determine
whether LIP and LAP have opposing and/or overlapping
actions on growth during normal mammary gland develop-
ment and breast cancer.
C/EBPδ gene
It has been demonstrated that C/EBPδ can regulate G0
growth arrest and apoptosis in HC11 mammary epithelial
cells [37]. Under optimal growth conditions, C/EBPδ does
not influence growth rate. In suboptimal growth condi-
tions, however, reduction of C/EBPδ via antisense
methodology increased proliferation, and overexpression
of C/EBPδ decreased proliferation via a G0 growth arrest
mechanism [37].
The ratio of full-length/truncated C/EBP
isoforms and the control of cell fate
Changes in the ratio of the C/EBPβ isoforms LAP/LIP have
been observed in mammary gland development [8,9], in
breast cancer [5,27], in ovarian cancer [38], in colorectal
cancer [39], in liver development [40], and in inductive
processes such as liver regeneration [41] and the
lipopolysaccharide-mediated acute phase response [42].
The general observation is that LIP levels are increased in
the more proliferative tumors or proliferative developmental
time points. For example, LAP expression is detected in
many breast cancer specimens, but the LIP isoform is more
highly expressed in the most aggressive, poorly differenti-
ated cancers [27]. Likewise, LAP is present at low levels in
the normal postmenopausal ovary and associated benign
tumors, but LAP expression increases in malignant samples,
while the LIP isoform is only detected in the malignant
tissues [38]. Similarly, LAP expression is increased in colon
cancer, but the LIP isoform is expressed at higher levels in
the more invasive Duke’s stage B tumors as compared with
the less invasive Duke’s stage A tumors [39].
On a similar note, N-terminal mutations of C/EBPα have
been identified in patients with acute myeloid leukemia
[43]. These mutations produce a truncated full-length
protein (20 kDa) that enhances the alternative translation
of the 30 kDa isoform. The mutant proteins (20 kDa) and
the 30 kDa isoform act as dominant negatives and block
the  trans-activation potential of the wild-type, full-length
isoform (42 kDa) [43].
In view of the fact that the ratio of full-length/truncated iso-
forms appears to be important in the control of cell fate, it
is important to consider the mechanisms that have been
suggested to generate the C/EBPβ isoforms.
Proteolytic generation of the LAP/LIP ratio
Both  in vivo proteolysis and in vitro proteolysis via a
calpain protease have been proposed as mechanisms to
generate the LIP isoform. Specific in vivo proteolytic cleav-
age of full-length C/EBPβ has been shown to occur in pre-
natal and neonatal mouse liver, and is dependent on
C/EBPα expression [44]. Other groups have reported that
artifactual  in vitro proteolytic cleavage of C/EBPβ can
occur and is dependent on the cell lysis procedure [26,45].
It has been suggested that mixing of the cytoplasmic and
nuclear compartments could expose the nuclear C/EBPβ
to cytoplasmic proteases or could activate nuclear,
calcium-dependent proteases via cytoplasmic calcium
[45]. Interestingly, Baer and Johnson also demonstrated
that proteolytic cleavage of LIP was dependent on the
presence of the leucine zipper region, and suggested that
dimerization could alter the protein’s folded structure and
render it more susceptible to proteolysis [45].
Translational control of the LAP/LIP ratio
Translational control of C/EBP isoform expression has
been most thoroughly studied in C/EBPα and C/EBPβ.
Because C/EBPα does not play a critical role in mammary
development or breast cancer, the present review will
emphasize the translational regulation of C/EBPβ.
Translation of mRNA can be regulated by AUG codons
within transcript leaders, referred to as upstream AUGs,
and associated upstream open reading frames (uORFs)
[46]. Upstream AUGs are commonly associated with onco-
genes and genes that regulate cellular growth and differen-
tiation [46]. C/EBPβ mRNA contains an out-of-frame uORF
that codes for a short, nine amino acid peptide located
between the LAP1 and the LAP2 translation start sites [25].
It has been hypothesized that both the LAP1 and the LAP2
translation start sites, as well as the uORF, are embedded
within a stem loop structure that may play an important role
in the regulation of AUG recognition [25] (Fig. 1).
Several different mechanisms have been described to
account for the differential expression of the C/EBPβ iso-
forms. A leaky ribosome scanning mechanism was initially
proposed to give rise to translational initiation at alternate
AUG codons [6]. It was suggested that if a leaky ribosome
scanning complex were to translate the uORF, it may favor
reinitiation further downstream at the LIP AUG codon,
which is positioned within a perfect Kozak consensus
sequence (see Fig. 1) [25,46]. However, Lincoln et al.
have found that the uORF does not facilitate translation of
the LIP isoform [47].
The laboratory of Leutz recently conducted an elegant study
to address the controversies surrounding the role of the
uORF in translational regulation of the LIP isoform versus the
proposed mechanism of proteolytic cleavage to generate LIP
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[34]. Strong evidence was presented to support the hypoth-
esis that the C/EBPβ isoforms arise via differential usage of
translation start sites rather than by proteolysis. Leutz and
coworkers showed that translation of the LIP isoform in cul-
tured cells is strictly regulated by the uORF, but translation of
LAP can occur either by leaky ribosome scanning or by reini-
tiation of ribosomes immediately after translation of the
uORF [34]. Interestingly, increased levels of eIF-4E and eIF-
2 favor LIP translation and function through associations with
the uORF (Fig. 1) [34]. Both eIF-2 [25] and eIF-4E [48] are
overexpressed in breast cancer and support our observation
of increased LIP translation in human tumors.
The final translational mechanism is centered around a
number of recent observations suggesting that LIP transla-
tion may be controlled by specific RNA binding proteins
that interact with the 5′ region of C/EBPβ mRNA [49].
One of these proteins, the CUG triplet repeat binding
protein (CUGBP1), has been characterized in detail.
CUGBP1 binds to the CCG repeat located within the
uORF of C/EBPβ mRNA [49]. The binding of CUGBP1 to
the 5′ region of C/EBPβ mRNA induces the translation of
the LIP isoform in rat and mouse liver during the acute
phase response, and in cell-free translation systems
[49,50]. These observations suggest that the production
of the dominant-negative LIP isoform can be controlled at
different levels through several mechanisms.
Regulation of C/EBPβ β activity by
phosphorylation and protein–protein
interactions
In addition to translational regulation of the LAP/LIP ratio,
post-translational phosphorylation and protein–protein
interactions have been shown to regulate the transcrip-
tional activity and the DNA binding activity of C/EBPβ.
Although most of these studies were not conducted in
mammary tissue, many of the observations may be valid
and worthy of investigation in breast development or
breast cancer. Phosphorylation of Ser276 by Ca2+-
calmodulin-dependent kinases in pituitary G/C cells has
been shown to stimulate the transcriptional activity of
C/EBPβ [51]. However, phosphorylation of Ser299 by
protein kinase C in rat liver attenuates DNA binding [52].
Additionally, phosphorylation by a ras-dependent mitogen-
activated protein kinase cascade at Thr235 in NIH 3T3
fibroblasts and in embryonic carcinoma P19 cells stimu-
lates the transciptional activity of human C/EBPβ (NF-IL6)
[53]. Also, phosphorylation of rat Ser105 or mouse
Thr217 in response to stimulators of cell proliferation such
as phorbol esters and growth factors (transforming growth
factor alpha) occurs via the protein kinase C and the p90
ribosomal S kinase pathways, and enhances the transacti-
vation of target genes [54,55].
Phosphorylation has also been shown to affect the sub-
cellular distribution of C/EBPβ. When overexpressed in a
mouse model or added to cultures of primary mouse hepa-
tocytes, tumor necrosis factor alpha induces the phospho-
rylation of Ser239 and the consequent nuclear export of
C/EBPβ, thereby preventing transcription of the albumin
gene [56]. However, osteoprotegerin ligand (which is a
member of the tumor necrosis factor superfamily) is
believed to facilitate nuclear import of C/EBPβ in the
mouse mammary epithelial cell line (HC11) and in mouse
primary mammary epithelial cells, thus allowing for the
transcriptional activation of β-casein [57].
Increasing evidence suggests that the C/EBPs are also
capable of protein–protein interactions with regulators of
cell-cycle progression or cell development, such as
retinoblastoma [58,59], Cdk2 and Cdk4 [60], NF-κB-p50
[61] and glucocorticoid receptor [62].
Conclusions
Of the six C/EBP genes, only C/EBPβ and C/EBPδ have
conclusive actions in the mammary gland. C/EBPδ
appears to be most important for growth arrest and
apoptosis, whereas C/EBPβ is necessary for growth and
differentiation.
The functional analysis of C/EBPβ is made more compli-
cated by the presence of the LIP and LAP isoforms, which
may have opposing actions on growth and are not always
expressed as a 1:1 ratio. Although C/EBPδ is variably
expressed in breast cancer specimens, a role in
tumorigenesis has not been demonstrated. Both LAP and
LIP are overexpressed in breast cancer, but LIP is often
more highly expressed in the more proliferative and
aggressive tumors. Likewise, the LIP isoform can induce
cellular proliferation when overexpressed in mouse
mammary glands or in cultured cells.
It is clear that additional studies need to be conducted to
address the translational and proteolytic regulation of
LIP/LAP, as well as to dissect out the individual functions
and role that LIP and LAP play in breast cancer. However,
these experiments are inherently difficult to conduct and
interpret for several reasons. First, endogenous C/EBPα,
C/EBPβ, C/EBPδ and C/EBPζ (CHOP) may be present
in mammary cells and may be capable of interacting with
LIP and LAP. Second, better antibodies need to be gener-
ated that can selectively recognize only the LIP or LAP
isoform in immunohistochemical applications. Protein
extraction and western blotting could then be avoided,
which would perhaps resolve some of the controversies
associated with the translational versus in vitro proteolytic
generation of C/EBPβ-LIP.
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